National and Kapodistrian University of Athens
Study of the bioactivity and toxicity of natural compounds in in vitro and in vivo systems
Abstract
dc:descriptionChios mastic (CM), the resin produced by Pistacia Lentiscus L., exerts several pharmacological activities that have been confirmed by numerous studies, however studies examining the toxicity of the product to support prospective pharmaceutical applications of CM are scarce. This thesis evaluates the safety of Chios mastic (CM) in Wistar rats through a tiered approach: a) an in vivo acute oral limit test, b) an in vivo bone-marrow micronucleus assay limit test, and c) a 90-day subchronic in vivo study focusing on liver effects. Chapter 2 assesses potential toxic effects of CM and characterizes potential biochemical disturbances in plasma and liver after the acute oral administration to Wistar rats at the limit dose. A limit test of the acute toxic class method was performed according to the OECD TG 423 with some modifications. Six male Wistar rats were orally administered by gavage a single dose of 2000 mg/kg bw CM, while five rats received the vehicle, followed by the clinical observation of the animals for 2 weeks. For metabolomics and histological study, blood was collected intermittently, and liver was sampled following the euthanasia of rats. During the observation period, no mortality or clinical signs of toxicity were observed. No statistical difference was observed in the body weight or organ weight of treated rats in comparison to the control group. The only tissue examined for histopathological alterations was the liver, which showed diffuse cytoplasmic clearing in 2 out of 6 treated rats suggesting glycogen accumulation. Plasma metabolomics study mainly indicated alterations in lipid metabolism in the treated group, affecting pathways of primary bile acid biosynthesis, linoleic acid metabolism and arachidonic acid metabolism. Lipid metabolism was also affected in liver of treated rats, altering primary bile acid biosynthesis pathway. CM can be classified in Category 5 (with an acute toxicity >2000-5000 mg/kg bw) or Unclassified according to OECD TG 423. In the absence of clinical signs of toxicity and gross organ pathology in treated group no target organs were identified. Metabolic perturbations of bile acid homeostasis were possibly associated with glycogen accumulation in the liver, which can be an adaptive response to the high dosing of CM. Chapter 3 investigates the genotoxicity of CM applying the limit test on the mammalian erythrocyte micronucleus assay in male Wistar rats. CM was administered by gavage to 5 rats at 2000 mg/kg bw for 3 days, while 5 rats received the vehicle and 5 rats received cyclophosphamide (positive control). Satellite groups of 3 rats were included for the negative control and CM-treated groups to collect plasma and bone marrow for chemical analyses. All rats were observed for mortality and clinical signs of toxicity during the dosing period. Rats were euthanatized 20 hours after the last treatment, necropsied, and bone marrow was collected for smear preparation. No mortality, clinical signs of toxicity, gross organ pathology, or body weight changes were observed in CM-treated rats compared to the negative control group. No statistically significant alteration of polychromatic erythrocytes (PCE) and the per-thousand incidences of micronucleated PCE in the bone marrow of CM-treated rats were observed. Bone marrow exposure to CM was unambiguously confirmed by the detection of the characteristic CM triterpenic acids in both bone marrow extract and plasma of CM-treated rats by UHPLCHRMS/MS analysis. In conclusion, no genotoxicity of CM was observed at the limit dose of 2000mg/kg bw on bone marrow erythrocytes. Chapter 4 examines the subchronic toxicity of CM in Wistar rats following 90 day oral administration via gavage at doses 0, 100, 400 and 1000 mg/kg bw in five groups of 10 animals per dose and sex. Body weight and clinical signs of toxicity were monitored during the dosing period, and gross necropsy, clinical pathology, liver histology and gene expression of Phase I liver metabolizing enzymes were studied. No mortality was observed in any of the tested doses, but moderate morbidity was observed in 1/10 male rats of the high dose group on week 5-7. In addition, decreased food consumption and body weight were observed on week 5, suggesting a transient toxicity in high dose male rats. The high dose affected the body weight of male rats, resulting in a significant decreased total body weight at the end of the study. Body weight of the medium dose female rats also showed significant decreases, however terminal body weight was not different from controls. Gross necropsy showed morphological alterations in small intestine of male and female high-dose groups. Clinical pathology parameters associated with liver damage were not increased in either male or female rats, suggesting no plausible liver injury. Liver histology of the high dose groups showed no significant alterations in males, while few mononuclear cell infiltrates were observed in 7/10 female rats, suggesting a minimal treatment-related inflammation in the liver. Gene expression analysis in the liver of the high dosed groups showed no significant alterations in P450 enzymes, apart from a significant induction in Cyp3a3 expression in both sexes. However, the human relevance of this finding is not fully elucidated. No induction of P450 enzymes involved in procarcinogen activation was determined. Overall, subchronic administration of CM to Wistar rats up to 400mg/kg bw did not show any signs of toxicity or effect at liver. The specific dose level corresponds to a daily consumption of approximately 24 gr of CM in human for 90 days, which is at least 10 times higher than the recommended dose for human consumption of 1- 2 gr for 15 days as traditional herbal medicinal product. Collectively, CM showed no acute toxicity and in vivo genotoxicity at the limit dose and was generally well tolerated over 90 days, with minimal, largely adaptive or transient findings mainly confined to the highest dose.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2024
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Psarou, Eirini-Christina
- Ψαρού, Ειρήνη-Χριστίνα
Subjects
dc:subject × 10Rights
- Language dc:language
- eng
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/61664